As part of the June issue, the European Respiratory Journal presents the latest in its series of podcasts. Deputy Chief Editor Don Sin interviews Steven D. Nathan (Inova Fairfax Hospital, Falls Church, VA, USA) about the PERFECT study, which showed that inhaled treprostinil does not demonstrate a positive risk–benefit ratio in favour of treatment in pulmonary hypertension associated with COPD.